Mark Stroh

Mark Stroh has extensive experience in the field of clinical pharmacology. Mark is currently serving as the Vice President and Head of Clinical Pharmacology at Intellia Therapeutics, Inc. Prior to this, they held the same position at CytomX Therapeutics, where they formed and led the company's first clinical pharmacology department. Mark has also worked at Genentech as a Senior Scientist in Clinical Pharmacology, providing support for multiple assets in various disease areas, particularly cancer immunotherapy. Additionally, Mark has experience as a Senior Investigator in Clinical PK/PD at Merck, where they made significant contributions to preclinical and late-stage programs in oncology. Throughout their career, they have demonstrated expertise in translational research and has held accountable roles in cross-functional teams and regulatory meetings.

Mark Stroh holds a PhD in Chemical Engineering from Cornell University. Prior to that, they completed their BS in Chemical Engineering from the University of California, Berkeley. After obtaining their PhD, they pursued a postdoctoral fellowship at Harvard Medical School.